Skip to content

Study · Randomized controlled trial · n = 62 · 2008

4 results

[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].

Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2008Cited by 2 (Europe PMC)

PMID18454096 (opens in a new tab)PepBankPUB-18454096
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with generalized anxiety disorder and neurasthenia, the anxiolytic effect of selank was similar to that of medazepam.

    In plain wordsIn patients with anxiety disorder and neurasthenia, selank relieved anxiety about as well as medazepam.

    Peptide
    Selank
    Outcome
    No significant changeAnxiolytic effect (psychometric scales)
    Study

    n = 62

    Comparator
    Medazepam
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The anxiolytic effects of both drugs were similar
    3 context sentences
    Summary · context
    Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied.
    Summary · context
    The effect of selank (30 patients) was compared to that of medazepam (32 patients).
    Summary · context
    Patient's state was assessed with psychometric scales (Hamilton, Zung, CGI).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with generalized anxiety disorder and neurasthenia, selank had an antiasthenic effect in addition to its anxiolytic effect, in the comparison with medazepam.

    In plain wordsIn patients with anxiety disorder and neurasthenia, selank also reduced weakness and fatigue symptoms in the comparison with medazepam.

    Peptide
    Selank
    Outcome
    IncreaseAntiasthenic effect
    Study

    n = 62

    Comparator
    Medazepam
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but selank had also antiasthenic and psychostimulant effects.
    3 context sentences
    Summary · context
    Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied.
    Summary · context
    The effect of selank (30 patients) was compared to that of medazepam (32 patients).
    Summary · context
    Patient's state was assessed with psychometric scales (Hamilton, Zung, CGI).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with generalized anxiety disorder and neurasthenia, selank had a psychostimulant effect in addition to its anxiolytic effect, in the comparison with medazepam.

    In plain wordsIn patients with anxiety disorder and neurasthenia, selank also had a stimulating effect in the comparison with medazepam.

    Peptide
    Selank
    Outcome
    IncreasePsychostimulant effect
    Study

    n = 62

    Comparator
    Medazepam
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but selank had also antiasthenic and psychostimulant effects.
    3 context sentences
    Summary · context
    Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied.
    Summary · context
    The effect of selank (30 patients) was compared to that of medazepam (32 patients).
    Summary · context
    Patient's state was assessed with psychometric scales (Hamilton, Zung, CGI).
  4. 04HumanRandomized controlled trialMechanism

    In patients with generalized anxiety disorder and neurasthenia treated with selank, the leu-enkephalin tau 1/2 parameter increased, mostly in patients with generalized anxiety disorder.

    In plain wordsIn patients treated with selank, a measure of how long leu-enkephalin lasts in the blood increased, mostly in those with anxiety disorder.

    Peptide
    Selank
    Outcome
    IncreaseLeu-enkephalin half-life (tau 1/2) during selank treatment
    Study

    n = 30

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The increase of this parameter and stronger positive correlations with anxiety level were observed during the treatment with selank mostly in patients with GAD.
    3 context sentences
    Summary · context
    Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied.
    Summary · context
    The effect of selank (30 patients) was compared to that of medazepam (32 patients).
    Summary · context
    Patient's state was assessed with psychometric scales (Hamilton, Zung, CGI).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.